1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Therapy Class Overview: Rituximab biosimilar

Therapy Class Overview: Rituximab biosimilar

  • October 2013
  • -
  • MP Advisors
  • -
  • 45 pages

Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year. This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales of ~$21b in 2012.Commercial success of biosimilars will be depend both on affordability and accessibility assuming that the “copy molecule” is at par on efficacy, safety and similarity with the branded product. Uptake and marketing strategy of Remicade biosimilar will be closely watched by investors as well as companies developing/marketing Biosimilars. In this report, we have analyzed the market opportunity of rituximab biosimilar.

What one would get if buy this report :

Challenges in developing rituximab Biosimilar- Worlwide and the emerging market experience in India and Mexico.
Rituximab biosililar pipeline, and the current status of clinical development
What are the Innovator's strategy in protecting rituximab franchise?
Competition to biosimilar rituximab from other innovative drugs.
Biosimilar guidelines in US, EU and other countries

Table Of Contents

Therapy Class Overview: Rituximab biosimilar

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global and Chinese Biosimilar Monoclonal Antibodies Industry, 2016 Market Research Report

Global and Chinese Biosimilar Monoclonal Antibodies Industry, 2016 Market Research Report

  • $ 2800
  • Industry report
  • December 2016
  • by Prof Research

The ’Global and Chinese Biosimilar Monoclonal Antibodies Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Biosimilar Monoclonal Antibodies ...

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017

  • $ 1995
  • Industry report
  • February 2017
  • by Currentpartnering

Summary The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the joint venture partnering ...

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022

  • $ 1500
  • Industry report
  • February 2017
  • by Kuick Research

“Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.